Ken Griffin Acurx Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$1.83 - $2.62 $9,150 - $13,100
-5,000 Reduced 35.21%
9,200 $17,000
Q2 2024

Aug 14, 2024
SELL
$1.64 - $2.79 $2,952 - $5,022
-1,800 Reduced 11.25%
14,200 $31,000
Q1 2024

May 15, 2024
BUY
$1.94 - $4.81 $15,908 - $39,442
8,200 Added 105.13%
16,000 $39,000
Q4 2023

Feb 14, 2024
BUY
$1.28 - $5.76 $9,984 - $44,928
7,800 New
7,800 $29,000

Others Institutions Holding ACXP

# of Institutions
26
Shares Held
1.25M
Call Options Held
9.3K
Put Options Held
9.7K
View Full List

About Acurx Pharmaceuticals, Inc.

ACXP Quotes by TradingView
  • Ticker ACXP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,556,600
  • Market Cap $9.48M
  • Description
  • Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...
More about ACXP
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email